novo nordisk cagrisema news - Search News

Novo Nordisk shares plunge

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Seeking Alpha · 1d

Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.

New York Post on MSN · 1d

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

10hon MSN

Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

1d

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

1don MSN

Novo Nordisk shares plunge 24% after CagriSema obesity drug trial results

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results